In addition, other potential biomarkers of response to anti‐EGFR rechallenge have been proposed such as anti‐EGFR‐induced skin toxicity and pre‐treatment values of neutrophil‐to‐lymphocyte ratio (NLR),15, 16 but larger prospective studies are needed. The gene discussed is EGFR; the disease is dermatological toxicity.